Edwards Lifesciences Corp
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Income
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net income | $241.4 | $331.5 | $622.1 | $687.9 |
| Other comprehensive income (loss), net of tax (Note 13): | ||||
| Foreign currency translation adjustments | (13.4) | 43.6 | (14.4) | 60.0 |
| Unrealized gain (loss) on hedges | 20.1 | (53.9) | 38.3 | (81.5) |
| Unrealized pension (costs) credits | — | (0.1) | 0.2 | — |
| Unrealized gain (loss) on available-for-sale investments | — | 0.8 | (0.4) | 1.9 |
| Other comprehensive income (loss), net of tax | 6.7 | (9.6) | 23.7 | (19.6) |
| Comprehensive income | 248.1 | 321.9 | 645.8 | 668.3 |
| Less: Comprehensive loss attributable to noncontrolling interest | (5.5) | (1.7) | (5.5) | (3.3) |
| Comprehensive income attributable to Edwards Lifesciences Corporation | $253.6 | $323.6 | $651.3 | $671.6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.